The Pharmaceutical Benefits Scheme listed a biosimilar adalimumab product on Tuesday, giving rheumatoid arthritis patients a lower-cost alternative to the originator biologic that has cost the Commonwealth more than $400 million annually in recent years.
Pharmacists can now dispense the biosimilar to new patients and, with prescriber consent, switch stable patients during repeat scripts. The Health Department said concessional card holders would pay about $7.70 per script, while general patients face roughly $30.90 — similar to other biologic tiers but with a lower government reimbursement behind the scenes.
Savings on the books
Arthritis Australia said typical general patients previously paid up to $4,200 a year in co-payments and safety-net gaps when adalimumab was the only listed anti-TNF option without a competing biosimilar. The patient group cautioned that switching should include nurse-led checks for injection-site reactions and disease flare monitoring.
The listing follows a price disclosure process that saw the originator’s ex-manufacturer price fall, but policymakers expect the biosimilar to drive further competition when tenders renew next July.
Clinical guardrails
The Therapeutic Goods Administration deemed the biosimilar equivalent in efficacy and safety for approved indications, including rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Gastroenterology societies issued a parallel statement reminding Crohn’s patients that switching biologics should be recorded in shared hospital–GP medication lists.
Rheumatologists at St Vincent’s Hospital in Sydney said they would run a phone hotline for two weeks to answer patient questions, after social media posts spread myths about biosimilars being “generics” with weaker potency.
Pharmacy cold chain
Adalimumab requires refrigeration at 2°C to 8°C. The Pharmacy Guild said most metropolitan pharmacies already stock biologic fridges, but rural sites may need extra deliveries twice weekly to avoid stockouts during the switch window.
Wholesalers said they had pre-positioned pallets in Brisbane and Perth distribution centres ahead of the listing date, anticipating a spike in script transfers after GP newsletters landed on Monday.
What patients should do
Patients should not switch silently: ask whether your prescriber wants a brand-specific script or permits pharmacy-led substitution. Keep injection diaries for six weeks after any change, and report flares through the usual specialist referral path rather than stopping doses cold.
For the budget, the listing is a rare piece of good news amid debates about Medicare levy thresholds — proof that biosimilar competition still works when formulary timing aligns with patent cliffs.
Specialist capacity
Rheumatology waiting lists in outer Melbourne and Brisbane remain above six months, meaning some patients may receive biosimilar scripts before they see a specialist face-to-face. Colleges urged GPs to coordinate with existing specialists before switching brands.